Skip to main content

Table 1 Clinico-pathological data of the patients and BM-status at BM1 and BM2 a

From: Disseminated tumor cells as selection marker and monitoring tool for secondary adjuvant treatment in early breast cancer. Descriptive results from an intervention study

  All patients Number (%)b BM1 neg Number (%)c BM1 pos Number (%)c P valued BM2 neg Number (%)c BM2 pos Number (%)c P valued
Number: n = 1090 n = 991 n = 94   n = 1002 n = 83  
Age at inclusion (median): 48 (range 23-69)
Menopausal status:
 Pre 592 (55.7) 540 (91.5) 50 (8.5) 0.19 547 (92.7) 43 (7.3) 0.60
 Post 325 (30.6) 287 (88.9) 36 (11.1) 296 (91.6) 27 (8.4)
 Unknown 146 (13.7) 138 (95.2) 7 (4.8) 134   11 (7.6)
 Missing 27   26   1   25 (92.4) 2  
Primary breast cancer surgery:        1.00      0.29
 Mastectomy 424 (39.4) 384 (91.2) 37 (8.8) 384 (91.2) 37 (8.8)
 Lumpectomy 653 (60.6) 594 (91.2) 57 (8.8) 60612 (93.1) 45 (6.9)
 Missing 13   13       1  
pT-status:        0.06      0.03
 pT 1a + b 67 (6.3) 55 (82.1) 12 (17.9) 65 (97.0) 2 (3.0)
 pT1c 500 (46.7) 451 (90.7) 46 (9.3) 464 (93.4) 33 (6.6)
 pT2 449 (41.9) 418 (93.3) 30 (6.7) 407 (90.8) 41 (9.2)
 pT3 49 (4.6) 44 (91.7) 4 (8.3) 43 (89.6) 5 (10.4)
 pT4 6 (0.6) 6 (100) 0 (0) 5 (83.3) 1 (16.7)
 Missing 19   17   2   18   1  
pN-status:        0.59      0.009
 pN0 462 (43.3) 424 (92.2) 36 (7.8) 428 (93.0) 32 (7.0)
 pN1 455 (42.6) 408 (89.9) 44 (9.7) 424 (93.8) 28 (6.2)
 pN2 99 (9.3) 93 (93.9) 6 (6.1) 86 (86.9) 13 (13.1)
 pN3 52 (4.9) 46 (88.5) 6 (11.5) 43 (82.7) 9 (17.3)
 Missing 22   20   2   21   1  
Histology:        0.02e      0.03e
 IDC 888 (82.4) 815 (92.3) 68 (7.7) 821 (93.0) 62 (7.0)
 ILC 106 (9.8) 90 (84.9) 16 (15.1) 92 (86.8) 14 (13.2)
 Others 84 (7.8) 74 (88.1) 10 (11.9) 79 (94.0) 5 (6.0)
 Missing 12   12     10   2  
Histological grade:        0.06      0.92
 Grade 1 83 (7.7) 75 (90.4) 8 (9.6) 80 (96.4) 3 (3.6)
 Grade 2 583 (53.9) 520 (89.8) 59 (10.2) 527 (91.0) 52 (9.0)
 Grade 3 404 (37.3) 378 (93.8) 25 (6.2) 376 (93.3) 27 (6.7)
 Unclassified 12 (1.2) 117 (91.7) 1 (8.3) 12 (100) 0 (0)
 Missing 8     1   7   1  
ER-status:        0.20      0.69
 Pos 814 (75.2) 737 (91.0) 73 (9.0) 749 (92.5) 61 (7.5)
 Neg 268 (24.8) 250 (93.6) 17 (6.4) 245 (91.8) 22 (8.2)
 Missing 8   4   4   8    
PR-status:             
 Pos 701 (64.9) 636 (91.1) 62 (8.9) 0.91 648 (92.8) 50 (7.2) 0.34
 Neg 369 (34.2) 337 (91.6) 310 (8.4) 3359 (91.0) 33 (9.0)
 Unclassified 10 (1.0) 9 (100) 1 (0) 10 (100) 0 (0)
 Missing 10   9        
Endocrine therapy:        0.52      0.41
 Yes 810 (76.2) 733 (90.8) 74 (9.2) 750 (92.9) 57 (7.1)
 No 253 (23.8) 233 (92.5) 19 (7.5) 230 (91.3) 22 (8.7)
 Missing 27   25   1   22   4  
HER2-statusf:        0.46      0.84
 Pos 117 (17.4) 109 (94.0) 7 (6.0) 108 (93.1) 8 (6.9)
 Neg 557 (82.6) 507 (91.4) 48 (8.6) 519 (93.5) 36 (6.5)
 Missing 51   48   2    49     
BM1:          
 Positive      79 (84.0) 15 (16.0) 0.004
 Negative      923 (93.1) 68 (6.9)
  1. aAll patients with a BM2 result are presented (column all patients). For the data according to BM1 and BM2 status, patients with a reported result on both analyses, are presented, n = 1085) (also see Figure 1).
  2. bValid percent.
  3. cThe percentages for the BM1 and BM2 analysis, in relation to the clinico-pathological variables.
  4. dFisher Exact test for variables with two categories; Linear-by-Linear Association for variables with more than two categories.
  5. “Unknown”, “Others”, Missing and “Unclassified” are not included in the statistical analysis.
  6. eComparison of infiltrating ductal carcinoma (IDC) and infiltrating lobular carcinoma (ILC).
  7. fPatients enrolled from June 2005 (n = 725); HER2 testing was not performed routinely before this time point.